MF59et
MF59et is a proprietary adjuvant formulation used in certain influenza vaccines to enhance the immune response. It is a variant of the original MF59 adjuvant, which was developed by Novartis (now part of GlaxoSmithKline) and is composed primarily of squalene oil, surfactants, and other stabilizing ingredients. The "et" suffix denotes a specific formulation or proprietary modification intended to optimize its efficacy, safety, or manufacturing process.
MF59et is designed to stimulate the innate immune system, promoting the activation of antigen-presenting cells and
The adjuvant's mode of action involves creating an immunostimulatory environment at the injection site, facilitating better
Safety profiles of MF59et-adjuvanted vaccines have generally been favorable, with common side effects including localized pain,
While specific details about "MF59et" may vary depending on the vaccine formulation and manufacturer, it remains